BAC's Q2 2026 8-K exhibit (primary source, period ended 6/30/2026) and secondary coverage confirm $9.1B net income and $1.21 EPS; BAC's P/B of ~1.54 versus JPM's 2.61 quantifies the premium the market pays for JPM's ~23% ROTCE versus lower peer returns.

Public.com shows the 16.42x P/E up 7.6% versus the 15.26x trailing-12-month average, Simply Wall St documents the 16.0x vs 14.3x peer / 12.2x industry comparison, and Macrotrends confirms the record $346.91 close — together showing the analyst upside targets require sustaining a best-in-class multiple, which is the crux of both the bull case (deserved premium for record profitability) and the bear case (multiple already stretched vs peers and its own history).

Multiple outlets covering the July 14 release reported the $7.70 EPS vs ~$5.55 consensus, $57.3B revenue vs ~$49.9B estimate, the 86% equity-trading surge to $6.0B (part of record $12.1B total Markets revenue), and the 30% IB fee jump; shares rose ~2.3% to $342.23 on earnings day and closed at a record $346.91 the next session.

Stockanalysis.com's JPM statistics page (as of the Jul 15, 2026 close) lists price $346.91, market cap $922.16B, trailing P/E 14.89, forward P/E 14.83, and P/B 2.61; note one aggregator (TradingEconomics) shows a somewhat higher ~$974B market cap figure, so the cap is best treated as roughly $920–975B.

Earnings coverage explicitly separates reported EPS of $7.70 (including $1.56/share of significant items — a $4.6B Visa share gain and ~$1.0B of equity-investment gains) from ex-items EPS of $6.14; this also means trailing-twelve-month EPS ($23.30) and the ~14.9 trailing P/E are modestly flattered by non-recurring gains.

stockanalysis.com showed the $346.91 close on Jul 15, 2026 with a 52-week range of $279.10–$351.24, and Macrotrends confirmed $346.91 as the all-time high closing price; the stock sits roughly 24% above its 52-week low.

Earnings coverage explicitly broke out the $5.6B pretax significant items (Visa gain $4.6B, equity investment gains $1.0B) and the normalized $16.9B net income / $6.14 EPS, meaning roughly $1.56 of the $7.70 reported EPS was non-recurring — the underlying beat versus consensus was real but far smaller than the headline 38.7% gap.

Stockanalysis.com's statistics page lists TTM revenue of $186.33B, TTM EPS of $23.30, total debt of $1.33T, 52-week appreciation of 20.16%, and beta of 0.98; for banks, debt is largely operational funding and conventional FCF/EV-EBITDA metrics are not standard, which is why EV and EV/EBITDA are generally not published for JPM.

stockanalysis.com's forecast page (S&P Global data, dated July 16, 2026) shows the 24-analyst count and the exact 8/4/12/0/0 ratings split; half of covering analysts are at Hold despite the overall Buy consensus.

stockanalysis.com lists average $364.81 (+5.16%), median $369 (+6.37%), high $420 (+21.07%), and low $305 (-12.08%) against the $346.91 close, indicating the Street sees modest upside after the stock's run.

MarketScreener's earnings flash and the official Business Wire release confirm the $7.70-vs-$5.59 beat driven by an investment-banking and trading surge; the $6.14 vs $7.70 discrepancy between reported and headline EPS across sources means the normalized beat is smaller than headlines suggest, so target raises built on the $7.70 print should be discounted somewhat.

Barchart/Investing.com data showed the 50-day MA at $304.02 with all MA signals (MA5–MA200) on buy; FX Leaders separately placed the 50-day SMA near $316 and the 200-day near $310 as of July 13, the small discrepancy reflecting different calculation dates. At a $346.91 close, price is ~10–14% above the 50-day and ~12% above the 200-day.

FX Leaders (July 13) identified $340–$343.45 as record-high resistance with $325/$316/$310 as staged supports; ChartMill flagged a support zone at $309.91–$310.79. The July 15 close of $346.91 is above the old $343.45 resistance, converting it into potential support.

Earnings-call coverage cites +15% ex-items revenue growth, NII of ~$25.62B (+10% YoY), markets revenue of $12.1B (+35%, equities +86%), expenses of $27.3B (+15%), and net charge-offs of ~$2.37B; figures are consistent across secondary summaries but the primary 8-K was not directly retrieved, hence medium confidence on the exact segment detail.

Q2 earnings coverage reports the board-approved raise to $1.65/quarter effective in Q3 2026 (a dividend raise, not a cut); stockanalysis.com shows the trailing $6.00 annual payout and 1.73% yield, which will rise as the new rate takes effect.

TipRanks' forecast page reports the $353.57 average and 9 Buy / 7 Hold mix, while stockanalysis.com (S&P Global) shows $364.81 across 24 analysts — the gap reflects different analyst pools and update timing, so the 'true' consensus sits in the $353–365 band.

Comparing both aggregators' average targets to the July 15 close shows single-digit implied upside; the key swing factors analysts cite are whether the Q2 investment-banking/trading windfall is durable (would push targets toward BofA's $408) versus normalization plus multiple compression toward the 14.3x peer average (would validate Baird's $305).

Financecharts reported a 20.44% trailing-12-month total return; FX Leaders reported the stock up more than 7% over the past month and nearly 19% over the past year as of mid-July 2026. A precise 6-month return figure was not directly published in retrieved sources, so the 12-month and 1-month figures anchor the trend.

Investing.com's technical page showed RSI(14) at 59.68 with a 'Neutral' signal, corroborated by a second reading of 59.62; both sit below the 70 overbought threshold.

Earnings-day coverage reported the expense guidance raise to $107.5B (from $105B) and the >2.5% premarket decline it initially triggered; the stock's subsequent close at $342.23 (+2.3%) and record $346.91 close on July 15 show the market ultimately looked through the higher cost outlook. This expense trajectory is the nearest-term technical risk to the rally's support levels.

Current P/B of 2.61 and P/E of ~14.7–14.9 are directly cited; the characterization versus JPM's own 5-year multiple history is directional (the sources retrieved did not provide an explicit 5-year average series), so this contextual claim carries low confidence and should be verified against a historical-multiples dataset.